The incidence of hypocalcemia was higher with denosumab than with zoledronic acid, likely due to the strong and rapid effect of denosumab in inhibiting osteoclastic activity by binding to RANKL.12 This evidence concerns the gene TNFSF11 and Hypocalcemia.